Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03397706 · OUTCOME

Half-life of Valganciclovir

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies · Source last updated 2025-03-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
hours
Interval / dispersion
Standard Deviation
Time frame
Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1

What was measured

PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1

Analysis population: The PK Analysis Set was used for all PK analyses and included all patients in the intent-to-treat population (defined as all enrolled patients) who had at least one postdose measurable PK concentration. The PK Analysis Set will be used for individual plasma concentration listings and summaries of plasma concentrations.

Groups in this outcome

Phase 1b Dose Escalation - 450 mg

valganciclovir: 450 mg QD or BID VRx-3996: 5 mg BID, 10 mg QD or BID

Phase 1b Dose Escalation - 900 mg

valganciclovir: 900mg QD or BID VRx-3996: 10 mg QD or BID, 20 mg QD on Days 1 to 4/week

Phase 2 RP2D - Capsule (VRx-3996)

valganciclovir: 900 mg QD VRx-3996: 20 mg QD on Days 1 to 4/week

Phase 2 RP2D - Tablet (VRx-3996)

valganciclovir: 900 mg QD VRx-3996: 20 mg QD on Days 1 to 4/week

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase 1b Dose Escalation - 450 mg11
Phase 1b Dose Escalation - 900 mg10
Phase 2 RP2D - Capsule (VRx-3996)23
Phase 2 RP2D - Tablet (VRx-3996)6

Reported measurements

Single-dose

Analysis denominator · Participants

GroupSource count
Phase 1b Dose Escalation - 450 mg11
Phase 1b Dose Escalation - 900 mg10
Phase 2 RP2D - Capsule (VRx-3996)23
Phase 2 RP2D - Tablet (VRx-3996)6
Values in hours · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Phase 1b Dose Escalation - 450 mg3.561.06Not reportedNot reportedNot reported
Phase 1b Dose Escalation - 900 mg3.131.43Not reportedNot reportedNot reported
Phase 2 RP2D - Capsule (VRx-3996)3.321.10Not reportedNot reportedNot reported
Phase 2 RP2D - Tablet (VRx-3996)2.171.68Not reportedNot reportedNot reported
Multiple-dose

Analysis denominator · Participants

GroupSource count
Phase 1b Dose Escalation - 450 mg0
Phase 1b Dose Escalation - 900 mg0
Phase 2 RP2D - Capsule (VRx-3996)7
Phase 2 RP2D - Tablet (VRx-3996)5
Values in hours · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Phase 2 RP2D - Capsule (VRx-3996)2.430.697Not reportedNot reportedNot reported
Phase 2 RP2D - Tablet (VRx-3996)2.611.55Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.06
        value
        3.56
      2. group Id
        OG001
        spread
        1.43
        value
        3.13
      3. group Id
        OG002
        spread
        1.10
        value
        3.32
      4. group Id
        OG003
        spread
        1.68
        value
        2.17
    denoms
    1. counts
      1. group Id
        OG000
        value
        11
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        23
      4. group Id
        OG003
        value
        6
      units
      Participants
    title
    Single-dose
  2. categories
    1. measurements
      1. group Id
        OG002
        spread
        0.697
        value
        2.43
      2. group Id
        OG003
        spread
        1.55
        value
        2.61
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        7
      4. group Id
        OG003
        value
        5
      units
      Participants
    title
    Multiple-dose
denoms
  1. counts
    1. group Id
      OG000
      value
      11
    2. group Id
      OG001
      value
      10
    3. group Id
      OG002
      value
      23
    4. group Id
      OG003
      value
      6
    units
    Participants
description
PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1
dispersion Type
Standard Deviation
groups
  1. description
    valganciclovir: 450 mg QD or BID VRx-3996: 5 mg BID, 10 mg QD or BID
    id
    OG000
    title
    Phase 1b Dose Escalation - 450 mg
  2. description
    valganciclovir: 900mg QD or BID VRx-3996: 10 mg QD or BID, 20 mg QD on Days 1 to 4/week
    id
    OG001
    title
    Phase 1b Dose Escalation - 900 mg
  3. description
    valganciclovir: 900 mg QD VRx-3996: 20 mg QD on Days 1 to 4/week
    id
    OG002
    title
    Phase 2 RP2D - Capsule (VRx-3996)
  4. description
    valganciclovir: 900 mg QD VRx-3996: 20 mg QD on Days 1 to 4/week
    id
    OG003
    title
    Phase 2 RP2D - Tablet (VRx-3996)
param Type
MEAN
population Description
The PK Analysis Set was used for all PK analyses and included all patients in the intent-to-treat population (defined as all enrolled patients) who had at least one postdose measurable PK concentration. The PK Analysis Set will be used for individual plasma concentration listings and summaries of plasma concentrations.
reporting Status
POSTED
time Frame
Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
title
Half-life of Valganciclovir
type
SECONDARY
unit Of Measure
hours

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice